Immunovirological Efficacy of Once-Daily Maraviroc Plus Ritonavir-Boosted Atazanavir After 48 Weeks in Naive HIV-Infected Patients

被引:8
|
作者
Pulido, Ildefonso [1 ]
Genebat, Miguel [1 ]
Alvarez-Rios, Ana I. [2 ]
De Pablo-Bernal, Rebeca S. [1 ]
Rafii-El-Idrissi Benhnia, Mohammed [1 ,3 ]
Pacheco, Yolanda M. [1 ]
Ruiz-Mateos, Ezequiel [1 ]
Leal, Manuel [1 ]
机构
[1] Univ Seville, Virgen del Rocio Univ Hosp, Infect Dis Microbiol & Prevent Med Clin Unit, Lab Immunovirol,Inst Biomed Seville IBiS,CSIC, Seville, Spain
[2] Univ Seville, Virgen del Rocio Univ Hosp, Dept Clin Biochem, IBiS,CSIC,SAS, Seville, Spain
[3] Univ Seville, Dept Biochem Mol Biol & Immunol, Sch Med, Seville, Spain
关键词
REVERSE-TRANSCRIPTASE INHIBITORS; ANTIRETROVIRAL TREATMENT; SPARING REGIMEN; HIV-1-INFECTED PATIENTS; VIROLOGICAL RESPONSE; NUCLEOSIDE; THERAPY; RALTEGRAVIR; TENOFOVIR/EMTRICITABINE; DARUNAVIR/RITONAVIR;
D O I
10.1089/vim.2016.0046
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Toxicities related to the use of nucleoside analogues have increased the interest in developing nucleoside-sparing regimens, mainly combining protease inhibitors with raltegravir. However, data regarding the use of CCR5-antagonists in this setting and in the naive scenario are scarce. The main objective was to analyze the immunovirological efficacy and tolerability of a low-dose, once-daily, maraviroc (MVC)-containing, nucleoside reverse transcriptase inhibitor-sparing dual therapy compared with standard triple therapy after 48 weeks for naive HIV-infected patients in the routine clinical practice setting. All naive HIV-infected patients with stable clinical condition that started antiretroviral treatment since February 1, 2008 to May 30, h 2012 were included. MVC clinical test was used to select candidate subjects to MVC therapy. Thirty-two subjects with MVC+ atazanavir/ritonavir (ATV/r) and 66 with standard triple therapy were analyzed. A comparable virological efficacy between groups was found after 48 weeks (87.5% vs. 80.3% of HIV undetectability, p = 0.37, MVC+ ATV/r and triple therapy groups, respectively). The CD4 recovery after 48 weeks was similar and more than 200 cells/mm(3) in both groups. No need of therapy changes or treatment discontinuations was observed in theMVC+ ATV/r group. Effect on lipid profile, high-sensitivity Creactive protein, and beta(2)-microglobulin was similar for both groups. Noteworthy, a significant increase of erythrocyte mean corpuscular volume was observed only in the triple therapy group. A nucleoside-sparing MVC-containing dual therapy showed similar immunovirological efficacy and tolerability than standard triple therapy in naive HIV-infected patients.
引用
收藏
页码:471 / 477
页数:7
相关论文
共 50 条
  • [31] Low-dose, once-daily atazanavir/ritonavir (200/100): An effective treatment for HIV-infected patients in Thailand
    Chetchotisakd, Ploenchan
    Anunnatsiri, Siriluck
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2008, 49 (02) : 230 - 231
  • [32] Pharmacokinetics of once-daily dolute-gravir and ritonavir-boosted darunavir in HIV patients: the DUALIS study
    Spinner, Christoph D.
    Kuemmerle, Tim
    Krznaric, Ivanka
    Degen, Olaf
    Schwerdtfeger, Christiane
    Zink, Alexander
    Wolf, Eva
    Klinker, Hartwig H. F.
    Boesecke, Christoph
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2017, 72 (09) : 2679 - 2681
  • [33] Saquinavir versus atazanavir once daily, each boosted with 100 mg ritonavir and combined with tenofovir/emtricitabine, result in comparable lipid changes after 24 weeks in treatment-naive HIV-infected patients
    Vrouenraets, S. M. E.
    Garcia, E. Fernandez
    Jackson, A.
    Raffi, F.
    Jayaweera, D. T.
    Katlama, C.
    Fisher, M.
    Slama, L.
    Hardy, D.
    Mauss, S.
    DeJesus, E.
    van Eeden, A.
    Prelutsky, D.
    Wit, F. W. N. M.
    Moyle, G.
    Reiss, P.
    ANTIVIRAL THERAPY, 2008, 13 (08) : A58 - A58
  • [34] GW433908/ritonavir once daily in antiretroviral therapy-naive HIV-infected patients: absence of protease resistance at 48 weeks
    MacManus, S
    Yates, PJ
    Elston, RC
    White, S
    Richards, N
    Snowden, W
    AIDS, 2004, 18 (04) : 651 - 655
  • [35] Effects of once-daily darunavir/ritonavir versus atazanavir/ritonavir on insulin sensitivity in HIV-infected persons over 48 weeks: results of an exploratory substudy of METABOLIK, a phase 4, randomized trial
    Overton, Edgar Turner
    Tebas, Pablo
    Coate, Bruce
    Ryan, Robert
    Perniciaro, Amy
    Dayaram, Yaswant K.
    De la Rosa, Guy
    Baugh, Bryan P.
    HIV CLINICAL TRIALS, 2016, 17 (02): : 72 - 77
  • [36] Clinical Outcomes Associated With Once-Daily Ritonavir-Boosted Darunavir Plus Tenofovir/Emtricitabine in HIV-Infected Patients Harboring at Minimum a M184V/I Resistance Mutation
    Sahloff, Eric G.
    Duggan, Joan M.
    ANNALS OF PHARMACOTHERAPY, 2019, 53 (01) : 50 - 55
  • [37] Simplification from tenofovir disoproxil fumarate plus lamivudine or emtricitabine plus ritonavir-boosted protease inhibitor to ritonavir-boosted atazanavir plus lamivudine in virologically suppressed HIV-infected adults with osteopenia: a pilot study
    Blanco, Jose L.
    Rojas, Jhon
    de Lazzari, Elisa
    Inciarte, Alexy
    Subirana, Mar
    Callau, Pilar
    Martinez-Rebollar, Maria
    Laguno, Montserrat
    Mallolas, Josep
    de la Mora, Lorena
    Torres, Berta
    Gonzalez-Cordon, Ana
    Martinez, Esteban
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2022, 77 (07) : 1974 - 1979
  • [38] Dose-finding study of once-daily indinavir/ritonavir plus zidovudine and lamivudine in HIV-infected patients
    Mallolas, J
    Blanco, JL
    Sarasa, M
    Giner, V
    Martínez, E
    García-Viejo, MA
    Arnaiz, JA
    Cruceta, A
    Soy, D
    Tuset, M
    Soriano, A
    Codina, C
    Pumarola, T
    Carné, X
    Gatell, JM
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2000, 25 (03) : 229 - 235
  • [39] Change to a once-daily combination including boosted atazanavir in HIV-1-infected children
    Macassa, Eugenia
    Delaugerre, Constance
    Teglas, Jean Paul
    Jullien, Vincent
    Treluyer, Jean Marc
    Veber, Florence
    Rouzioux, Christine
    Blanche, Stephane
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2006, 25 (09) : 809 - 814
  • [40] Pharmacokinetics of once-daily tenofovir, emtricitabine, ritonavir and fosamprenavir in HIV-infected subjects
    Parks, David A.
    Jennings, Harold C.
    Taylor, Christopher W.
    Acosta, Edward P.
    AIDS, 2007, 21 (10) : 1373 - 1375